Actions

CD34: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 20: Line 20:
<span style="color:navy">'''Diagnostic role'''</span>  
<span style="color:navy">'''Diagnostic role'''</span>  


*xxxxx
*CD34 is commonly used to identify the primitive nature of early lymphoid or myeloid cells i.e. blast cells of ALL and AML
*Rare very primitive cases of acute leukaemia may be identified solely through their expression of CD34 and CD45
*CD45 is also expressed by regenerating cells in marrow and also by regenerating haematogones so caution is necessary in interpretation in regenerating marrows 





Revision as of 12:44, 17 May 2023


Summary
Often regarded as a marker of primitive phenotype, CD34 is expressed by many cases of ALL (around 50%) and slightly fewer cases of AML around (40%). CD34 is also expressed by regenerating cells in marrow. It is particularly expressed by regenerating B lymphocytes (haematogones), but is generally absent from mature haematopoietic cells.



Normal expression and function

CD34 is a membrane protein that is likely to play a role in the retention of cells within the stem cell niche where it may also contribute to their subsequent maturation. CD34 is acquired at the stage of pluripotent stem cells and is retained by committed stem cells before being lost as the cells mature. CD34 is also expressed by mast cells and by some non-haematopoietic cells particularly endothelial cells.


Diagnostic role

  • CD34 is commonly used to identify the primitive nature of early lymphoid or myeloid cells i.e. blast cells of ALL and AML
  • Rare very primitive cases of acute leukaemia may be identified solely through their expression of CD34 and CD45
  • CD45 is also expressed by regenerating cells in marrow and also by regenerating haematogones so caution is necessary in interpretation in regenerating marrows



Other relevant information:

xxxxx




SUMMARY TABLES


Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name


Expression in primitive cell types
AML CMML B ALL Burkitt T ALL ETP ALL <I> MPAL <I> Hgns <I>
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx


Expression in mature T cell neoplasms*
ATLL CTCL/Sezary T-PLL T-LGL NK-LGL
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx